THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES
Author(s)
Becker R, Zaccagnini P, Rattana S, Ovation Research Group, Highland Park, IL, USA
Presentation Documents
OBJECTIVE: Brazil's universal access to HIV treatment and drug price reductions have affordably treated large segments of the country's HIV-infected population. Several countries in Central America have large HIV-infected populations without access to care. This analysis examines the feasibility of applying Brazil's universal access to treatment and drug price reductions given the economic conditions in three Central American countries: Guatamala (n=71,050), El Salvador (n=19,400), and Belize (n=2,400). METHODS: Each country's HIV population not currrently receiving antiretroviral therapy was estimated. For each population, the cost of two-drug and three-drug combination antiretroviral therapy was estimated by applying 2000 Brazilian prices (in U.S. dollars). The ratio of drug costs to gross domestic product was determined to measure each country's relative ability to pay for the cost of treatment. The Brazilian rate of cost savings from averted hospitalizations was subtracted from each country's drug cost estimates to determine total cost of treatment. RESULTS: In Guatamala, the drug costs for treating the HIV population ranges between $54.2 (0.117% of GDP) and $335.1 (0.725%) million depending on whether double or triple combination therapy is used. The costs range between $14.8 (0.062%) and $91.5 (0.381%) million in El Salvador, and between $1.8 (0.232%) and $11.3 (1.433%) in Belize. Potential hospitalization costs averted were $80.5 million in Guatamala, $22.0 million in El Salvador, and $2.7 million in Belize. Given these costs averted, the total cost of treatment ranges between -$28.5 (cost savings) and $252.4 million in Guatamala depending on whether double or triple combination therapy is used, between -$7.9 and $68.8 million in El Salvador, and between -$888.8 thousand and $8.6 million in Belize. CONCLUSIONS: Since the ratio of antiretroviral drug costs to GDP was 0.041% in Brazil in 2000, these three Central American countries may have more difficulty affording antiretroviral therapy unless double combination therapy is used.
Conference/Value in Health Info
2002-05, ISPOR 2002, Arlington, VA, USA
Value in Health, Vol. 5, No. 3 (May/June 2002)
Code
IN4
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)